Recruiting PHASE1 Schizophrenia

Trial studying safety and effects for Schizophrenia

Official title Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder

ClinicalTrials.gov ID: NCT05025605

What this study is testing

What is BXCL501 80 µg?

an investigational sublingual film being studied as a potential treatment for schizophrenia in children and adolescents is designed to activate alpha‑2 adrenergic receptors, which can reduce norepinephrine activity and produce calming effects

Also referred to as Dexmedetomidine.

Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.

What it's testing
The study aims to find out whether BXCL501 is safe and effective for treating acute agitation in young people with bipolar disorder or schizophrenia.
Who it's for
Children and adolescents who are experiencing sudden, severe agitation and have been diagnosed with bipolar disorder or schizophrenia.
What's involved
Participants will receive the investigational drug BXCL501 and undergo safety monitoring and assessments during the study.
  • Phase 1: an early, usually small safety study
  • You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance.

A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.

Who can take part

Ages 10 to 17

You may be able to join if

  • Male and female people between the ages of 10-17 years, inclusive, with bipolar disorder (DSM-5 criteria) and 13-17 years, inclusive, in people with...
  • Patients who are judged to be clinically agitated at Screening and Baseline with a total score of ≥14 on the 5 items comprising the PANSS Excited...
  • Patients who have a score of ≥ 4 on at least 1 of the 5 items on the PEC at Baseline.
  • Participants who agree to use a medically acceptable and effective birth control method

You likely can't join if

  • Patients with agitation caused by acute intoxication, including alcohol or drugs of abuse (with the exception of THC) during urine screening.
  • Use of benzodiazepines or other hypnotics or oral or short-acting intramuscular antipsychotic drugs in the 4 hours before study treatment.
  • Patients who are judged to be at significant risk of suicide.
  • Patients with serious or unstable medical illnesses.
  • Patients who have received an investigational drug within 30 days prior to the current agitation episode.
  • Patients who are considered by the investigator, for any reason, to be an unsuitable candidate for receiving the study drug.

The study team makes the final eligibility decision.

Where it's taking place

  • Anaheim, California, United States
  • Hialeah, Florida, United States
  • Atlanta, Georgia, United States
  • Decatur, Georgia, United States
  • DeSoto, Texas, United States

Compensation & support

This study's listing mentions compensation or reimbursement.

No amount is published here - ClinicalTrials.gov has no reliable field for payment or travel support. Ask the study team what's actually covered (payment for your time, travel, parking, or other study costs), and never join a trial for the compensation alone.

Questions & answers

Do participants get paid in this trial?

This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 10 years to 17 years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Anaheim, California, United States; Hialeah, Florida, United States; Atlanta, Georgia, United States; Decatur, Georgia, United States; DeSoto, Texas, United States. Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.